Versant Capital Management’s Enzo Biochem, Inc. ENZ Stock Holding History

Versant Capital Management’s Portfolio ENZ Stock Details ENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-24	Closed	–	–	1740
2019 Q4	$0	Hold	24	–	–	﹤0.01%	1628
2019 Q3	$0	Hold	24	–	–	﹤0.01%	1634
2019 Q2	$0	Hold	24	–	–	﹤0.01%	1753
2019 Q1	$0	Sell	24 -1,134	-98%	-$3.71K	﹤0.01%	1768
2018 Q4	$3K	Hold	1,158	–	–	﹤0.01%	1198
2018 Q3	$4K	Hold	1,158	–	–	﹤0.01%	1181
2018 Q2	$6K	Hold	1,158	–	–	﹤0.01%	1055
2018 Q1	$6K	Hold	1,158	–	–	﹤0.01%	1041
2017 Q4	$9K	Hold	1,158	–	–	﹤0.01%	951
2017 Q3	$12K	Sell	1,158 -185	-14%	-$2.05K	0.01%	788
2017 Q2	$14K	Sell	1,343 -287	-18%	-$2.67K	0.01%	742
2017 Q1	$13K	Hold	1,630	–	–	0.01%	754
2016 Q4	$11K	Hold	1,630	–	–	0.01%	805
2016 Q3	$8K	Buy	1,630 +24	+1%	+$143	﹤0.01%	891
2016 Q2	$9K	Hold	1,606	–	–	0.01%	829
2016 Q1	$7K	Hold	1,606	–	–	﹤0.01%	885
2015 Q4	$7K	Buy	+1,606	New	+$6.78K	﹤0.01%	864

Other funds holding ENZ

HFA

Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return

EGA

Evermore Global Advisors Summit, New Jersey $26.3M AUM 7.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Versant Capital Management's ENZ Position: Q1 2020 in Review

Versant Capital Management sold out of Enzo Biochem, Inc. (ENZ) in Q1 2020, closing a stake of 24 shares.

Versant Capital Management first reported a position in ENZ in Q4 2015 and held it in 17 quarters. The position peaked at $14K in Q2 2017. 76 funds tracked by Wall St. Rank hold ENZ as of Q1 2020.

Versant Capital Management reported no remaining Enzo Biochem, Inc. position as of Q1 2020 after selling out during the quarter.
Versant Capital Management sold 24 Enzo Biochem, Inc. shares in Q1 2020.
Versant Capital Management first reported a position in Enzo Biochem, Inc. in Q4 2015 and held it in 17 quarters.
Versant Capital Management's Enzo Biochem, Inc. position peaked at $14K in Q2 2017.
76 funds tracked by Wall St. Rank held Enzo Biochem, Inc. as of Q1 2020.

Based on Versant Capital Management's 13F filing for Q1 2020, filed 17 Apr 2020.